Treat-to-target in systemic lupus erythematosus: where are we today?
Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-to-target approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year.
Rheumatology Unit, Department of Internal Medicine, University of Pisa, Italy. marta.mosca@med.unipi.it
Marta
M
Mosca
Dimitrios T
DT
Boumpas
Ian N
IN
Bruce
Ricard
R
Cervera
Laszlo
L
Czirjak
Thomas
T
Dörner
Frédéric
F
Houssiau
Soren
S
Jacobsen
Matthias
M
Schneider
Josef S
JS
Smolen
Alexandre E
AE
Voskuyl
Ronald F
RF
van Vollenhoven
D018450:Disease Progression; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*; D010347:Patient Care Planning; D011788:Quality of Life; D016896:Treatment Outcome